Company news

Catalyst Pharmaceuticals, Inc. news in 2024

Catalyst Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 15, 2024

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

November 24, 2024

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

November 12, 2024

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update

November 5, 2024

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

October 21, 2024

Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

October 7, 2024

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024

September 30, 2024

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan

September 23, 2024

Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update

August 6, 2024

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

July 23, 2024

Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

July 21, 2024

Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

May 29, 2024

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

May 27, 2024

Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024

Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024

April 30, 2024

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

April 21, 2024

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

March 27, 2024

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

March 26, 2024

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

March 12, 2024

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

March 4, 2024

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 27, 2024

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

February 26, 2024

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

February 20, 2024

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

February 13, 2024

Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering

January 8, 2024

Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

January 4, 2024

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

January 3, 2024

Calls in 2024

Decks in 2024